INTERLEUKIN-2 IN THERAPY OF HEMATOLOGIC MALIGNANCIES

被引：0

|

作者：

SZNOL, M ^{[1
]}

PARKINSON, DR ^{[1
]}

机构：

[1] NCI,DIV CANC TREATMENT,CANC THERAPY EVALUAT PROGRAM,INVEST DRUG BRANCH,EPN 715,ROCKVILLE,MD 20852

来源：

BLOOD | 1994年 / 83卷 / 08期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：2020 / 2022

页数：3

相关论文

共 50 条

[21] INTERLEUKIN-2 AND CANCER-THERAPY
HANCOCK, BW
REES, RC
CANCER CELLS-A MONTHLY REVIEW, 1990, 2 (01): : 29 - 32
[22] INTERLEUKIN-2 IN CANCER-THERAPY
PARKINSON, DR
SEMINARS IN ONCOLOGY, 1988, 15 (06) : 10 - 26
[23] FIBROMYALGIA AND INTERLEUKIN-2 THERAPY FOR MALIGNANCY
WALLACE, DJ
MARGOLIN, K
WALLER, P
ANNALS OF INTERNAL MEDICINE, 1988, 108 (06) : 909 - 909
[24] The role of interleukin-2 in cancer therapy
Gore, M
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 1996, 11 (05) : 281 - 283
[25] HYPOTHYROIDISM AFTER INTERLEUKIN-2 THERAPY
HARTMANN, LC
URBA, WJ
STEIS, RG
SMITH, JW
VANDERMOLEN, L
CREEKMORE, SP
LONGO, DL
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (05) : 686 - 687
[26] Interleukin-2 therapy in HIV infection
Pahwa, S
Morales, M
AIDS PATIENT CARE AND STDS, 1998, 12 (03) : 187 - 197
[27] INTERLEUKIN-2 THERAPY FOR HUMAN CANCER
VANHOESEL, QGCM
LUNG, 1990, 168 : 1069 - 1074
[28] Prognostic markers in interleukin-2 therapy
Lissoni, P
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 1996, 11 (05) : 285 - 287
[29] INTERLEUKIN-2 THERAPY FOR MALIGNANT HEMANGIOENDOTHELIOMA
MASUZAWA, M
ASAI, T
NISHIOKA, K
NISHIYAMA, S
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1989, 93 (04) : 563 - 563
[30] ADRENAL INSUFFICIENCY AND INTERLEUKIN-2 THERAPY
VANDERMOLEN, LA
SMITH, JW
LONGO, DL
STEIS, RG
KREMERS, P
SZNOL, M
ANNALS OF INTERNAL MEDICINE, 1989, 111 (02) : 185 - 185

← 1 2 3 4 5 →